Cancer Therapeutics CRC, a small-molecule drug discovery company based in Bundoora, Australia, has selected Dotmatics' informatics platform to provide tools for querying and analyzing data at its research sites.
Cancer Therapeutics CRC focuses on generating lead and preclinical-stage drug candidates. In particular, it looks for potential treatments that target cancer pathways associated with the tumor microenvironment or growth in breast, prostate, melanoma, lung, and brain cancers.
The firm has selected Dotmatics' Browser and Vortex programs to support data sharing and communication with its academic, research, and industrial partners; and to increase its research output.
Last month, Dotmatics announced that Progenra, a Malvern, Penn.-based biotechnology company, had licensed its informatics platform to support drug discovery and development efforts around the ubiquitin-proteasomal pathway of cellular protein regulation (BI 5/25/2012).
Also in May, Basilea Pharmaceutica, a Swiss biopharmaceutical company, licensed the Dotmatics platform to manage its preclinical research data (BI 5/18/2012).